Update on metformin for osteoarthritis treatment.

IF 5.3 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2025-09-25 DOI:10.1007/s10787-025-01902-y

Ben-Zheng Li, He-Xin Wei, Shu-Zhi Li, Yong-Ze Yang, An-Ren Zhang, Hong-Zhang Guo

引用次数: 0

Abstract

Osteoarthritis (OA) is a prevalent degenerative joint disease among middle-aged and elderly individuals. Metabolic syndrome (Met S), a group of clinical conditions characterized by abnormal metabolic processes, includes obesity as one of its primary risk factors. Recent studies have demonstrated a significant association between metabolic syndrome and osteoarthritis. Metformin, a classical hypoglycemic agent, is commonly prescribed for patients with type 2 diabetes mellitus who do not achieve adequate control through diet and physical activity alone. Metformin has gradually gained attention in the treatment of OA due to its anti-inflammatory, antioxidant, and metabolic function-enhancing properties. This review summarizes the latest research on metformin by examining recent clinical and animal studies, systematically analyzing its mechanisms, and assessing its clinical potential in treating OA.

查看原文本刊更多论文

二甲双胍治疗骨关节炎的最新进展。

骨关节炎（OA）是一种在中老年人群中普遍存在的退行性关节疾病。代谢综合征（Met S）是一组以代谢过程异常为特征的临床疾病，肥胖是其主要危险因素之一。最近的研究表明代谢综合征和骨关节炎之间存在显著的联系。二甲双胍是一种经典的降糖药，通常用于仅通过饮食和体育活动无法达到适当控制的2型糖尿病患者。二甲双胍因其抗炎、抗氧化、增强代谢功能等特性，在OA治疗中逐渐受到重视。本文综述了二甲双胍的最新研究成果，包括近期的临床和动物研究，系统分析其作用机制，评估其治疗OA的临床潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]